Defining a future role for radiogenic therapy

J. M. Kaminski, R. J. Kaminski, A. P. Dicker, J. L.C. Urbain

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

The goal of cancer therapy is to eliminate the cancer and/or to arrest further growth while decreasing normal tissue toxicity, i.e. to increase the therapeutic ratio. This review focuses on a group of therapeutics that are either (1) directly stimulated by radiation to produce either directly or indirectly cytotoxic agents (i.e. genes under the control of a radiation inducible promoter that produce a cytotoxic protein or an enzyme that converts a prodrug to an active form, respectively); (2) auger-electron emitting radiolabelled oligonucleotides, antibodies, nucleotide analogues, or other small molecules that are internalized; (3) radiation inducible genes that produce a ligand or transporter (or the like) which then can be targeted by cytotoxic agents (e.g. radiolabelled substance). We have termed this group of therapeutics radiogenic therapy.

Original languageEnglish (US)
Pages (from-to)289-294
Number of pages6
JournalCancer Treatment Reviews
Volume27
Issue number5
DOIs
Publication statusPublished - Jan 1 2001

    Fingerprint

Keywords

  • Antibody
  • Cancer
  • Genes
  • Radiation
  • Somatostatin

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Kaminski, J. M., Kaminski, R. J., Dicker, A. P., & Urbain, J. L. C. (2001). Defining a future role for radiogenic therapy. Cancer Treatment Reviews, 27(5), 289-294. https://doi.org/10.1053/ctrv.2001.0236